Sangamo Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 405
- Market Cap
- $170.2M
- Introduction
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT00748501
- Locations
- ๐บ๐ธ
The University of Kansas Medical Center (KU), Kansas City, Kansas, United States
๐บ๐ธCalifornia Pacific Medical Center (CPMC), The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States
๐บ๐ธUniversity of California, Irvine; MDA ALS and Neuromuscular Center,, Orange, California, United States
Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT00665145
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy
- Interventions
- Biological: SB-509Other: Placebo
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 91
- Registration Number
- NCT00476931
- Locations
- ๐บ๐ธ
Laszlo J. Mate', M.D., West Palm Beach, Florida, United States
๐บ๐ธUpstate Clinical Research, Albany, New York, United States
๐บ๐ธNerve and Muscle Center of Texas, Houston, Texas, United States
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy
- Interventions
- Other: Normal Saline
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 110
- Registration Number
- NCT00406458
- Locations
- ๐บ๐ธ
Bradenton Research Center, Bradenton, Florida, United States
๐บ๐ธAdvanced Medical Research, LLC, Lakewood, California, United States
๐บ๐ธCoordinated Clinical Research, La Jolla, California, United States
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Drug: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])Procedure: Sham Surgery
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT00400634
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
๐บ๐ธBaylor College of Medicine, Houston, Texas, United States
๐บ๐ธUniversity of Alabama, Birmingham, Birmingham, Alabama, United States
Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT00252850
- Locations
- ๐บ๐ธ
Rush University Medical Center, Chicago, Illinois, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy
- Conditions
- Diabetic Neuropathy
- First Posted Date
- 2005-05-10
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT00110500
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Sangamo Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT00087789
- Locations
- ๐บ๐ธ
Rush University Medical Center, Chicago, Illinois, United States
๐บ๐ธUniversity of California San Diego, San Diego, California, United States